Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Investment analysts at Edison Inv. Res issued their FY2025 EPS estimates for Basilea Pharmaceutica in a research note issued to investors on Thursday, March 27th. Edison Inv. Res analyst J. Prakash expects that the company will post earnings of $4.76 per share for the year.
Basilea Pharmaceutica Price Performance
Shares of OTCMKTS:BPMUF opened at $54.00 on Monday. The company has a current ratio of 4.10, a quick ratio of 3.27 and a debt-to-equity ratio of 5.70. The company’s 50-day moving average price is $52.99 and its 200 day moving average price is $52.68. Basilea Pharmaceutica has a fifty-two week low of $38.60 and a fifty-two week high of $54.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- What is Insider Trading? What You Can Learn from Insider Trading
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- Do ETFs Pay Dividends? What You Need to Know
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is the Euro STOXX 50 Index?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
